Delving into the Latest Updates on Azilsartan Kamedoxomil with Synapse

主要目的：比较空腹和餐后单次给药条件下，珠海润都制药股份有限公司生产的美阿沙坦钾片（规格：80mg）与Takeda Pharma A/S持证的美阿沙坦钾片（商品名：易达比®/EDARBI®，规格：80mg）在健康受试者中吸收程度和速度的差异。通过主要药代动力学参数，评价两者是否生物等效。次要目的：通过观察健康受试者单次口服受试制剂和参比制剂后的安全性指标，评价美阿沙坦钾片的安全性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of Asartan Potassium Tablets (specification: 80 mg) produced by Zhuhai Rundu Pharmaceutical Co., Ltd. and Asartan Potassium Tablets (trade name: EDARBI®/EDARBI®, specification: 80 mg) licensed by Takeda Pharma A/S in healthy subjects under the conditions of single administration on an empty stomach and after a meal. To evaluate whether the two are bioequivalent by the main pharmacokinetic parameters. Secondary objective: To evaluate the safety of Asartan Potassium Tablets by observing the safety indicators of the test preparation and the reference preparation after a single oral administration to healthy subjects.

Start Date15 Oct 2024

Sponsor / Collaborator

Zhuhai Rundu Pharmaceutical Co., Ltd.

CTR20243700

/ CompletedNot Applicable

美阿沙坦钾片在健康受试者中餐后状态下的开放、随机、交叉生物等效性试验

[Translation] An open, randomized, crossover bioequivalence study of Asartan Potassium Tablets in healthy volunteers in the fed state

主要试验目的研究餐后状态下单次口服受试制剂美阿沙坦钾片（规格：80mg，浙江华润三九众益制药有限公司生产）与参比制剂美阿沙坦钾片（商品名：易达比®；规格：80mg；Takeda Ireland Ltd.生产）在健康受试者体内的药代动力学，评价餐后状态口服两种制剂的生物等效性。次要试验目的评估受试制剂美阿沙坦钾片（规格：80mg）与参比制剂易达比®（规格：80mg）在健康受试者中的安全性。

[Translation]

Main study objectives To study the pharmacokinetics of the test preparation, Asartan Potassium Tablets (Specification: 80 mg, produced by Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd.) and the reference preparation, Asartan Potassium Tablets (trade name: Edabi®; Specification: 80 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. Secondary study objectives To evaluate the safety of the test preparation, Asartan Potassium Tablets (Specification: 80 mg) and the reference preparation, Edabi® (Specification: 80 mg) in healthy subjects.

Start Date12 Oct 2024

Sponsor / Collaborator

Zhejiang Gaozhi Pharmaceutical Technology Co., LtdStartup

CTR20243579

/ CompletedNot Applicable

美阿沙坦钾片在健康受试者中空腹/餐后状态下的开放、随机、交叉生物等效性试验

[Translation] An open, randomized, crossover bioequivalence study of Asartan potassium tablets in healthy subjects under fasting/fed conditions

主要研究目的：研究空腹/餐后状态下单次口服受试制剂美阿沙坦钾片（规格：80mg，陕西白鹿制药股份有限公司生产）与参比制剂美阿沙坦钾片（商品名：易达比®；规格：80mg；Takeda Ireland Ltd.生产）在健康受试者体内的药代动力学，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂美阿沙坦钾片（规格：80mg）与参比制剂易达比®（规格：80mg）在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation, Miasartan Potassium Tablets (Specification: 80 mg, produced by Shaanxi Bailu Pharmaceutical Co., Ltd.) and the reference preparation, Miasartan Potassium Tablets (trade name: Edabi®; Specification: 80 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study: to evaluate the safety of the test preparation, Miasartan Potassium Tablets (Specification: 80 mg) and the reference preparation, Edabi® (Specification: 80 mg) in healthy subjects.

Start Date09 Oct 2024

Sponsor / Collaborator

Shaanxi BAI LU Pharmaceutical Co. Ltd.

100 Clinical Results associated with Azilsartan Kamedoxomil

Login to view more data

100 Translational Medicine associated with Azilsartan Kamedoxomil

Login to view more data

100 Patents (Medical) associated with Azilsartan Kamedoxomil

Login to view more data

745

Literatures (Medical) associated with Azilsartan Kamedoxomil

06 Jan 2025·Regenerative Biomaterials

Azithromycin-loaded PLGA microspheres coated with silk fibroin ameliorate inflammation and promote periodontal tissue regeneration

Article

Author: Zhou, Yangyang ; Sun, Lu ; Xu, Yue ; Zhang, Li ; Xing, Liangyu ; Hu, Meilin ; Gao, Feng ; Liu, Dayong ; Li, Haocong ; Chen, Xiaoyu ; Ouyang, Zhaoguang ; Deng, Zhe ; Lian, Tengye ; Wang, Ying ChengYao ; Liu, Chunyi ; Wang, Zhengyang

AbstractPeriodontitis, a widespread inflammatory disease, is the major cause of tooth loss in adults. While mechanical periodontal therapy benefits the periodontal disease treatment, adjunctive periodontal therapy is also necessary. Topically applied anti-inflammatory agents have gained considerable attention in periodontitis therapy. Although azithromycin (AZM) possesses excellent anti-inflammatory properties, its bioavailability is limited owing to poor water solubility and the absence of sustained release mechanisms. Herein, we synthesized biodegradable microspheres (AZM@PLGA-SF) for sustained AZM release to locally ameliorate periodontal inflammation and facilitate periodontal tissue regeneration. AZM was encapsulated in poly (lactic-co-glycolic acid) (PLGA) microspheres (AZM@PLGA) using single emulsion-solvent evaporation, followed by surface coating with silk fibroin (SF) via electrostatic adsorption, reducing the initial burst release of AZM. In vivo, local treatment with AZM@PLGA-SF microspheres significantly reduced periodontal inflammation and restored periodontal tissue to healthy levels. Mechanically, the formulated microspheres regulated the periodontal inflammatory microenvironment by reducing the levels of pro-inflammatory cytokines (tumor necrosis factor -α, interleukin [IL]-6, interferon-γ, IL-2, and IL-17A) in gingival crevicular fluid and promoted the expression of anti-inflammatory cytokines (IL-4 and IL-10). AZM@PLGA-SF microspheres demonstrated excellent biological safety. Therefore, we introduce an anti-inflammatory therapy for periodontitis with substantial potential for mitigating periodontal inflammation and encouraging the repair and regeneration of periodontal tissues.

01 Jan 2025·Theriogenology

Dexamethasone and azithromycin enhance goat sperm preservation quality by regulating lipid metabolism

Article

Author: Ling, Yinghui ; Wang, Lei ; Xu, Yongjie ; Zhang, Zijun ; Ren, Chunhuan ; Wang, Mingyue ; Sun, Shixin ; Cao, Hongguo ; Shen, Wenzheng

Phospholipase A (PLA) in goat semen aggregates with egg yolk in semen diluent, leading to sperm death. The aim of this study is to address the issue of sperm death caused by the interaction between PLA and egg yolk, and to explore the protective effect and metabolic regulation mechanism of the combination of dexamethasone (DXMS) and azithromycin (AZM) on goat sperm under low temperature conditions. At a low temperature of 4 °C, different concentrations of DXMS were added to semen diluents containing 30 μg/mL AZM to detect the quality of goat sperm. The optimal concentration of DXMS was determined to be 20 μg/mL. On the 5th day of storage, antioxidant capacity, total cholesterol (TC) levels, energy metabolism, and metabolomics analysis were performed on the sperm of the 20 μg/mL DXMS group. The results showed that there was no aggregation caused by the interaction between PLA and egg yolk in the group containing 30 μg/mL AZM at 4 °C. 20 μg/mL DXMS significantly improved sperm motility, plasma membrane integrity, acrosome integrity, glutathione peroxidase (GPX) (P < 0.05), catalase (CAT) (P < 0.01), and superoxide dismutase (SOD) activity (P < 0.01). The content of reactive oxygen species (ROS) and Fe²⁺ significantly decreased (P < 0.01), while the content of ATP (P < 0.01) and TC (P < 0.05) significantly increased. Through metabolomics analysis, a total of 56 differential metabolites (P < 0.05) were screened, including 5a, 6-Anhydrotetracycline, Betamethasone, and 11-Dehydrocorticosterone, mainly enriched in 8 metabolic pathways (P < 0.05), including steroid hormone biosynthesis, glycerophospholipid metabolism, and choline metabolism in cancer. Among them, 5 metabolic pathways are related to lipid metabolism. The results indicate that AZM effectively inhibits the aggregation of PLA and yolk, and the combination of AZM and DXMS enhances the preservation quality of goat sperm during low-temperature preservation by regulating lipid metabolism.

01 Jan 2025·Journal of Infection and Chemotherapy

Three cases of hospitalized Legionella pneumonia patients successfully treated with lascufloxacin

Article

Author: Nakanishi, Yosuke ; Ito, Akihiro ; Ishida, Tadashi ; Sato, Ryoju ; Kawataki, Masanori

Legionella pneumonia is one of the major causes of severe pneumonia, in which treatment delay might lead to a poor prognosis. Therefore, as far as possible, early diagnosis and treatment of Legionella pneumonia is essential. Regarding the antimicrobials for Legionella pneumonia, fluoroquinolones, such as levofloxacin, or macrolides, such as azithromycin (AZM), are recommended in Japan and other countries. Lascufloxacin (LSFX), the newest fluoroquinolone developed in Japan, has been in use in daily clinical practice since January 2020. However, there are only few reports of Legionella pneumonia cases treated with LSFX. Here, we report three cases of hospitalized Legionella pneumonia patients that were successfully treated using LSFX. All three patients were admitted to the medical ward on admission, although one patient was subsequently transferred to the ICU for mechanical ventilatory management due to worsening of the pneumonia on day 3. All patients improved and were discharged following LSFX treatment (the patient admitted to the ICU was treated using LSFX + AZM combination therapy) without any severe adverse events. LSFX might be considered to be the first antibiotic choice for Legionella pneumonia, similar to levofloxacin. However, further data regarding the treatment of Legionella pneumonia cases using LSFX are needed to evaluate its efficacy and safety.

2

News (Medical) associated with Azilsartan Kamedoxomil

04 Nov 2019

·www.stada.com

STADA invests $660 Million USD in Takeda’s OTC portfolio in Russia/CIS to become a major player in these branded markets

Bad Vilbel, Moscow, November 5, 2019 – STADA Arzneimittel AG (together with its subsidiaries ‘STADA’ or ‘the Group’) has agreed to acquire a portfolio of selected products from Takeda Pharmaceutical Company Limited for a total value of $660 Million USD. The portfolio of approximately 20 selected over-the-counter (‘OTC’) and prescription pharmaceutical assets sold inter alia in Russia, Georgia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan will be divested to STADA Arzneimittel AG. The portfolio includes OTC-vitamins and food supplements, plus selected products within the cardiovascular, diabetes, general medicine, and respiratory therapeutic areas. Included in the transaction is the key product Cardiomagnyl, a well-known name and category leader in Russia, which is used to prevent blood clots, as well as the newer, patent-protected Nesina (for type II diabetes treatment) and Edarbi (angiotensin II receptor blocker for blood pressure control). The acquired portfolio complements STADA’s existing portfolio and capabilities in Russia which include medicines from 16 of 20 therapeutic groups of the best-selling products in retail pharmacies. The transaction will enable the Group to continue expanding its consumer health business in Russia and the CIS. It is expected that the highly capable approximately 500-strong sales and marketing team from Takeda’s business will transfer to STADA on completion of the transaction, which is expected in the first quarter of 2020. In addition, Takeda and STADA will enter into manufacturing and supply agreements in connection with the acquisition under which Takeda will continue to supply the products to STADA. The acquisition is expected to be financed by new debt financing. Peter Goldschmidt, CEO of STADA, commented: “This is STADA’s largest acquisition to date and will position us as a major player in a large and structurally growing market. This transaction also reflects the ambitions of STADA as we continue expanding the business internationally – both organically and through acquisitions – and continue generating significant operating efficiencies worldwide. STADA’s branded products are already well-represented in the most popular pharmacy categories in our key markets. However, we are continuing to expand our portfolio of branded generics, to strengthen our position in strategic niches and to develop new market segments.” Advisers to STADA on this transaction included: Nomura (M&A) and Kirkland & Ellis LLP (legal). About STADA Arzneimittel AG STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

AcquisitionBiosimilar

26 Jul 2017

·www.bioportfolio.com

Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

Summary Arbor Pharmaceuticals LLC Arbor is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of latestage prescription products. It also offers generic prescription and development stage products. Arbor's prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US. Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Azilsartan Kamedoxomil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Azilsartan Kamedoxomil	C09CA09	DB08822

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	EU	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	IS	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	LI	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	NO	Takeda Pharma A/S	07 Dec 2011
Hypertension	US	Azurity Pharmaceuticals, Inc.	25 Feb 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Hypertension	Phase 2	CL	Takeda Pharmaceutical Co., Ltd.	01 Jun 2007
Hypertension	Phase 1	RU	Takeda Pharmaceutical Co., Ltd.	01 Jan 2009
Hypertension	Phase 1	CL	Takeda Pharmaceutical Co., Ltd.	01 Jan 2009
Hypertension	Phase 1	US	Takeda Pharmaceutical Co., Ltd.	01 Jan 2009
Essential Hypertension	Phase 1	MX	Takeda Pharmaceutical Co., Ltd.	01 Jun 2007
Essential Hypertension	Phase 1	US	Takeda Pharmaceutical Co., Ltd.	01 Jun 2007
Essential Hypertension	Phase 1	AR	Takeda Pharmaceutical Co., Ltd.	01 Jun 2007
Hypertension	Preclinical	US	Takeda Pharmaceutical Co., Ltd.	01 Jan 2009
Hypertension	Preclinical	RU	Takeda Pharmaceutical Co., Ltd.	01 Jan 2009
Hypertension	Discovery	CL	Takeda Pharmaceutical Co., Ltd.	01 Jan 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


APAO2024	Not Applicable	Uveitis TNF-α	-	Azithromycin (Sham)	jascvlgsww(gmavflpkrx) = iflbpwumis wvbvzequpi (wcacjoxrag )	Positive	22 Feb 2024
				Topical AZM 1.5%	jascvlgsww(gmavflpkrx) = ymtglnmvxk wvbvzequpi (wcacjoxrag )
NCT02541669 (CTgov)	Phase 1	Hypertension	64	TAK-491 (Open Label: TAK-491 40 mg)	hfcjtwifin(snhvyvcstg) = chsluotzez hcichnyhkf (swabsnxrii, lesyfiqlmh - hkbgazdxje) View more	-	05 Feb 2020
				TAK-491 (Open Label: TAK-491 80 mg)	hfcjtwifin(snhvyvcstg) = wnbrdqiuzu hcichnyhkf (swabsnxrii, xkfbnamwjt - uzgkfbvuvn) View more
NCT02517866 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Essential Hypertension	380	Azilsartan Medoxomil	ixkmlzarna(nlxwrqnixk) = ndyzqtwies krwoampxkb (hexwmvyztt, mxgcdjtrxn - jbrwxjurpw) View more	-	01 Mar 2019
NCT02480764 (CTgov)	Phase 3	Essential Hypertension	612	Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	xblrqfxuut(ciscwieyhd) = ofgnuuoegh waslfeuxcx (kdnvafhyho, rfmpelbfcy - klpnvbxdly) View more	-	11 Feb 2019
				Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg)	xblrqfxuut(ciscwieyhd) = cwlqfjgzlv waslfeuxcx (kdnvafhyho, lnvalzfhqn - gbrvcbawxx) View more
ESH2018	Not Applicable	Metabolic Syndrome \| Hypertension	32	Azilsartan medoxomil 40 mg	(qudixbcbxi) = aiqflcwjdp xtaclgaqua (pnsyiklpwy ) View more	Positive	01 Jun 2018
				Azilsartan medoxomil 80 mg	(qudixbcbxi) = qquksacyau xtaclgaqua (pnsyiklpwy ) View more
[PP.12.25] (ESH2017)	Not Applicable	Diabetes Mellitus, Type 2 \| Hypertension	30	Azilsartan medoxomil 40 mg	cjphbafrqw(hdakwmxstc) = vswkggrxyd eppcfchsei (rqapoglkxb )	Positive	01 Sep 2017
				Azilsartan medoxomil 80 mg	cjphbafrqw(hdakwmxstc) = mkcckucnsg eppcfchsei (rqapoglkxb )
[PP.22.13] (ESH2017)	Not Applicable	Essential Hypertension	-	Azilsartan medoxomil 80 mg	fqedwqctid(dgvsvfjhsy) = zkklkqwbed lymdzdgqbj (jacfxpkbty, 1.8) View more	Positive	01 Sep 2017
NCT02203916 (CTgov)	Phase 3	Essential Hypertension	328	Azilsartan medoxomil placebo (Placebo)	lpfanjxqcw(qnzdnviitm) = piuawhitjj iwqpsymvcf (epumlvudgd, qwldgtqmvx - kyupylijti) View more	-	19 Dec 2016
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	lpfanjxqcw(qnzdnviitm) = dnlzfezhyq iwqpsymvcf (epumlvudgd, gkzaruleun - tzjhhxldww) View more
NCT00695955 (Pubmed \| Clin Exp Hypertens) Manual	Phase 3	Essential Hypertension	669	chlorthalidone+azilsartan medoxomil	(xbrhtpjani) = fhstrtclac komgzazveq (qkcuydlfjk ) View more	Positive	01 Jan 2016
				hydrochlorothiazide+azilsartan medoxomil	(xbrhtpjani) = lnxdusyriv komgzazveq (qkcuydlfjk ) View more
NCT01496430 (CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Hypertension	105	Placebo (Placebo QD)	lbgshlqvsy(guycrzzcmf) = bueoodsmya ojqonxbhoy (suelroowak, zdzypsjgdu - wuofjzcckb) View more	-	06 May 2015
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg QD)	lbgshlqvsy(guycrzzcmf) = jrvyedvjdy ojqonxbhoy (suelroowak, vikjnsosel - fjbpzpoqmz) View more